Germonpre 2008 (SYRINGES).

Study name	Low molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in patients with stage IIIB and IV NSCLC undergoing a cisplatin based first line chemotherapy: the SYRINGES Trial
Methods	Study type: interventional Allocation: randomized Endpoint classification: safety/efficacy study Intervention model: parallel assignment Masking: open‐label Primary purpose: treatment
Participants	Locally advanced or metastatic NSCLC (stage IIIB or IV)
Interventions	Intervention: enoxaparin daily 1 mg/kg/day sc Control: no enoxaparin Co‐intervention: cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (every 3 weeks for 4 cycles)
Outcomes	Progression‐free survival Incidence of total documented thromboembolic and hemorrhagic events
Starting date	June 2008
Contact information	Paul R Germonpre, MD PhD Universiteit Antwerpen
Notes	Sponsor: University Hospital, Antwerp Universiteit Antwerpen Status as of August 2017: Completed (not published yet)